Topics:

All Content

A new study found that the androgen receptor splice variant 7 is associated with resistance to two therapies for metastatic castration-resistant prostate cancer.

Oncologists should be experts at farewells. I often write a note of condolence if I have not made personal contact with the patient or family close to the time of death.

In this interview we discuss the American Society of Clinical Oncology’s (ASCO) health information and patient record initiative called CancerLinQ.

Multiple myeloma patients may already suffer from sensory deficits prior to treatment, likely due to disease-related decreases in peripheral innervation density.

HER2-positive breast cancer patients treated with targeted therapy and chemo were less likely to have a pathologic complete response if they had a PIK3CA mutation.

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

This review will focus largely on the effects of systemic cytotoxic treatment on cognitive function, reflecting what has been most extensively studied in the literature.

Much of the existing research into the phenomenon commonly referred to as “chemobrain” has been descriptive, and we know enough now to identify some patients at risk for cognitive changes after a diagnosis of cancer.

With the growing number of cancer survivors, there is increased interest in understanding and preventing post-treatment sequelae that may limit full recovery to prediagnosis health.

Cognitive dysfunction during and following treatment for cancer, often referred to as “chemobrain,” is an adverse effect of cancer treatment that may interfere with patients’ ability to resume their precancer lifestyle, with subsequently reduced quality of life.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.